GTG signs on with seventh US PPO
20 June, 2013 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) has reached an agreement with US PPO FedMed that will allow insurance claims for its BrevaGEN breast cancer risk test to be expedited for 40 million lives.
Compumedics finds funding for order backlog
14 June, 2013 by Dylan Bushell-EmblingCompumedics (ASX:CMP) has finally secured the short-term funding needed to help it process a significant order backlog for its diagnostics products.
Biosensors open a portal to improving cancer treatment
13 June, 2013Advanced technologies help researchers visualise cancer spreading and improve drug delivery.
Patrys’s antibody written up in melanoma journal
13 June, 2013 by Dylan Bushell-EmblingAn article summarising the early-stage development of Patrys’s PAT-SM6 as a melanoma treatment has been published in Melanoma Research.
Bionomics fills quota for renal cancer trial
12 June, 2013 by Dylan Bushell-EmblingBionomics (ASX:BNO) has completed enrolment for the first clinical trial involving a vascular disrupting agent - the company’s BNC105 candidate - with an mTOR inhibitor.
Patrys nabs NZ patent for cancer antibody
11 June, 2013 by Dylan Bushell-EmblingPatrys (ASX:PAB) has picked up a patent covering anticancer antibody PAT-LM1 in a second market - New Zealand.
Award for excellence in health and medical research
11 June, 2013An infectious diseases researcher has been recognised for his dedication to patients and biomedical research.
Sunscreen each day keeps ageing skin at bay
04 June, 2013Australian research has found that daily use of broad-spectrum sunscreen slows the ageing process of skin, as well as preventing skin cancer.
Newcastle Uni researchers target bowel disease
03 June, 2013 by Dylan Bushell-EmblingResearchers from the University of Newcastle, the University of Colorado and Aerpio Therapeutics have demonstrated the potential for a new class of drugs to treat inflammatory bowel disease.
Biotron to present HIV trial data at IAS 2013
31 May, 2013 by Dylan Bushell-EmblingBiotron (ASX:BIT) will present data from its phase IIa trial of BIT225 in HIV at IAS 2013 in Malaysia.
Funding boost for dementia research
31 May, 2013The Queensland Premier has announced significant funding support for dementia research.
Biolife secures AU patent for cancer vaccine
29 May, 2013 by Dylan Bushell-EmblingBiolife has secured Australian IP protection for its HER-Vaxx cancer vaccine, as it heads towards a backdoor ASX listing and phase II trials.
Immune protein protects against diabetes
29 May, 2013A mechanism by which a person’s immune system is dysregulated in autoimmune diabetes has been found and described in a paper published in Nature Immunology.
Nominations open for CSL Florey Medal
28 May, 2013Seeking Australian researchers who have made significant achievements in biomedical science and/or in advancing human health.
Funding for multiple sclerosis research
24 May, 2013Research into multiple sclerosis prevention and treatment has received a $1 million boost from the Australian Government.
